Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Cash from Operations (2016 - 2025)

Altimmune (ALT) has disclosed Cash from Operations for 16 consecutive years, with 11897000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 56.13% to 11897000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 66352000.0, a 15.06% increase, with the full-year FY2024 number at 79848000.0, down 5.33% from a year prior.
  • Cash from Operations was 11897000.0 for Q3 2025 at Altimmune, up from 19350000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 11897000.0 in Q3 2025 to a low of 27118000.0 in Q3 2024.
  • A 5-year average of 18135210.53 and a median of 18108000.0 in 2024 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: crashed 350.13% in 2021, then soared 56.13% in 2025.
  • Altimmune's Cash from Operations stood at 21967000.0 in 2021, then grew by 21.22% to 17306000.0 in 2022, then increased by 4.47% to 16533000.0 in 2023, then decreased by 10.48% to 18265000.0 in 2024, then soared by 34.86% to 11897000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Cash from Operations are 11897000.0 (Q3 2025), 19350000.0 (Q2 2025), and 16840000.0 (Q1 2025).